top of page

Clinical trials and international collaborations

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study

Merseburger A, et al. Lancet Oncol. 2022

https://www.sciencedirect.com/science/article/pii/S1470204522005605?via%3Dihub

 

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial

James ND, et al. JNCI Cancer Spectr. 2022

https://academic.oup.com/jncics/article/6/4/pkac043/6649740?login=true

 

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

Parker CC, et al. PLoS Med. 2022

https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003998

 

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)

James ND, et al. IJC. 2022

https://onlinelibrary.wiley.com/doi/10.1002/ijc.34018

 

The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses

Marsden T, et al. PLoS ONE. 2022

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0259672

 

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Attard G, et al. Lancet. 2022

https://www.sciencedirect.com/science/article/pii/S0140673621024375?via%3Dihub

 

Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

Rush HL, et al. JCO. 2022

https://ascopubs.org/doi/10.1200/JCO.21.00728?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

 

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

Saad F, et al. Lancet Oncol. 2021

https://www.sciencedirect.com/science/article/pii/S1470204521004022?via%3Dihub

 

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial

Ali A, et al. JAMA Oncol. 2021

https://jamanetwork.com/journals/jamaoncology/fullarticle/2776418

 

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

Clarke N, et al. Ann. Oncol. 2019

https://www.sciencedirect.com/science/article/pii/S0923753420325527

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study.

Attard G, et al. JAMA Oncology. 2019

https://jamanetwork.com/journals/jamaoncology/fullarticle/2737089

Sequencing of agents in castration-resistant prostate cancer.

Lorente D, et al. Lancet Oncol. 2015

https://www.sciencedirect.com/science/article/pii/S1470204515700331?via%3Dihub

bottom of page